M. E. Garza
View M. E. Garza's Articles BY TICKER:
ACAR.OB,
ACCP.OB,
ALKS,
ALTH,
ALXA,
AMPE,
AMRN,
ARIA,
ARNA,
ARRY,
ASTM,
ASTX,
AVEO,
AVNR,
BCRX,
BLRX,
BPAX,
CBLI,
CCEL.OB,
CDXC.OB,
CLDA,
CLRT,
CLSN,
CNDO,
CORT,
CRIS,
CTIC,
CVM,
CYTR,
DCTH,
DEPO,
ECTE,
EPCT.PK,
EPIX.PK,
EXEL,
FURX,
GALE,
GSK,
GTHP.OB,
HALO,
HEB,
HLF,
IBIO,
IDIX,
IMUC,
INCY,
INHX,
IPCI,
KERX,
KVPBQ.PK,
LGND,
MDGN,
MEDX,
MNTA,
MSTX,
NAVB,
NBIX,
NBS,
NEPH.OB,
NEPT,
NPSP,
NVAX,
NVLT.OB,
NWBO,
OCLS,
OMPI,
ONCS.OB,
ONCY,
OPK,
OXGN,
PBTH,
PGNX,
PLX,
POZN,
PPHM,
PSTI,
PVCT.OB,
QGEN,
RGEN,
RNN,
RXPC.PK,
SGEN,
SIGA,
SLXP,
SNWV.OB,
SPPI,
SYN,
TDLP.OB,
THLD,
THRX,
TKMR,
TSPT,
VICL,
XOMA,
YMI,
ZLCS
- With The RNAi Sector Heating Up Again This Is Now The Undervalued Biotech Stock To Watch
- Taking Note Of IntelliPharmaCeutics' Now Imminent FDA Decision
- AVEO Management Excited About Statistically Significant Improvement Shown In Phase III TIVO-1 Trial
- Neptune's Dividend Catalyst Finally In Play
- Medgenics: Former CEO Of Celgene Believes In His Newest Biotech Venture
- Can Array BioPharma's Breakout Run Hold Or Continue?
-
Confirmation Of Anticipated Catalyst Likely To Fuel Neptune's Share Prices
- Will Shares Of Aastrom Really Triple From Today's Levels Within A Year?
- 2 Healthcare Stocks That May Surprise In The Near Term
- Darling Dendreon Takes Hits As Speculators Continue To Bet On Immunotherapy Plays
- Frost Swoops In To Buy More Cheap Prolor Biotech Shares
- Adventrx CEO Attempting To Prime His Firm For A Comeback
- Incyte's Potential Blockbuster Pipeline Asset Makes It An Attractive Takeover Target
- Pozen Shares On The Rebound Since European Migraine Licensing Deal
- Closer Look: OMPI's Acquisition Rumors And Price Targets
- Should Biotech Investors Start Paying Attention To Parasitic Pig Worms And Autoimmune Diseases?
- Are Tides Changing For Herbalife After Massive Sell-Off?
-
Is The Novavax 'New Paradigm' Worth A Second Look?
- Q&A: Astex CEO Focused On Creating Value For Investors In 2012
- Solid Fundamental Bet: Shares Of Marine Omega-3 Phospholipids Leader Ready Climb
- Insider Buy At Novavax Spurs Speculation
- Krill Oil Based Drug Candidate Could Unseat Glaxo's Blockbuster Lovaza
- Why Ampio's Big Rebound Run May Not Be Done
- President Of Prolor Biotech Bullish About His Firm's Pipeline And Positioning
- Corcept Therapeutics: Is There More To Come?
- Protalix Reinforces Case For Taliglucerase Alfa; Healthcare Sector Volume Keeps Rising
- Closer Look: BioLineRx Snags Another Hep-C License Agreement
- 2 Biotechs On Teva's Radar Screen
- Neurocrine Biosciences Still Worth Watching
- OncoSec Medical's President And CEO Lists His Firm's 2012 Milestones
- More Drama From Cell Therapeutics
- Another Catalyst For Protalix BioTherapeutics